[go: up one dir, main page]

JO3435B1 - تركيبة دوائية صلبة تحتوي على أملوديبن ولوسارتان - Google Patents

تركيبة دوائية صلبة تحتوي على أملوديبن ولوسارتان

Info

Publication number
JO3435B1
JO3435B1 JOP/2015/0219A JOP20150219A JO3435B1 JO 3435 B1 JO3435 B1 JO 3435B1 JO P20150219 A JOP20150219 A JO P20150219A JO 3435 B1 JO3435 B1 JO 3435B1
Authority
JO
Jordan
Prior art keywords
amlodipine
disintegrant
losartan
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
JOP/2015/0219A
Other languages
English (en)
Inventor
Soo Woo Jong
Roh Leedong
Il Kim Yong
Taek Im Ho
Su Yoon Young
Hyun Park Jae
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Application granted granted Critical
Publication of JO3435B1 publication Critical patent/JO3435B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Inorganic Chemistry (AREA)

Abstract

يقدم الاختراع الحالي تركيبة دوائية لمنع او علاج إضطرابات القلب والأوعية الدموية التي تحتوي على لوسارتان أو ملح منه مقبول دوائياً، واملوديبين او ملح منه مقبول دوائياً، ومفتت وعامل تغليف. كما تظهر التركيبة وفقاً للإختراع الحالي التي لها أفضل تركيبة ونسب مثالية لمفتت إلى عامل تغليف قوة كافية ومعدلات ذوبان عالية في بيئات درجة حموضة مختلفة وبالتالي، تكون مفيدة لتحضير تركيبة صلبة ممتازة تظهر كفاءة توصيل محسنة للعقار وإمكانية الإستقرار بالتخزين.
JOP/2015/0219A 2014-09-30 2015-09-08 تركيبة دوائية صلبة تحتوي على أملوديبن ولوسارتان JO3435B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20140131834 2014-09-30
KR1020150123167A KR102369607B1 (ko) 2014-09-30 2015-08-31 암로디핀 및 로잘탄을 포함하는 고형 약제학적 조성물

Publications (1)

Publication Number Publication Date
JO3435B1 true JO3435B1 (ar) 2019-10-20

Family

ID=55630854

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2015/0219A JO3435B1 (ar) 2014-09-30 2015-09-08 تركيبة دوائية صلبة تحتوي على أملوديبن ولوسارتان

Country Status (20)

Country Link
US (1) US10034862B2 (ar)
JP (1) JP2017530137A (ar)
KR (1) KR102369607B1 (ar)
CN (2) CN112716951A (ar)
AR (1) AR101860A1 (ar)
CO (1) CO2017003913A2 (ar)
CR (1) CR20170125A (ar)
DO (1) DOP2017000084A (ar)
EC (1) ECSP17022124A (ar)
JO (1) JO3435B1 (ar)
MX (1) MX377103B (ar)
MY (1) MY188302A (ar)
PH (1) PH12017500536A1 (ar)
RU (1) RU2698703C2 (ar)
SG (1) SG11201702364VA (ar)
SV (1) SV2017005417A (ar)
TW (1) TWI681773B (ar)
UY (1) UY36331A (ar)
WO (1) WO2016052866A1 (ar)
ZA (1) ZA201703015B (ar)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6673798B2 (ja) * 2016-10-12 2020-03-25 日本化薬株式会社 カペシタビンを有効成分とするフィルムコート医薬製剤
WO2018093096A2 (en) * 2016-11-15 2018-05-24 Hanmi Pharm. Co., Ltd. Pharmaceutical complex preparation comprising amlodipine, losartan and rosuvastatin
CN115666564B (zh) * 2020-06-09 2024-07-16 韩美药品株式会社 在单层片剂中包括氨氯地平、氯沙坦和氯噻酮的预防或治疗心血管系统疾病的药学上组合制剂

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5138069A (en) 1986-07-11 1992-08-11 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
CA2179067A1 (en) 1993-12-23 1995-06-29 Gordon Creston Campbell, Jr. Polymorphs of losartan and the process for the preparation of form ii of losartan
KR101247583B1 (ko) * 2006-12-08 2013-03-26 한미사이언스 주식회사 암로디핀 또는 이의 약제학적 허용가능한 염, 및 로자탄또는 이의 약제학적 허용가능한 염을 함유하는 약제학적조성물
US20110206761A1 (en) 2008-09-04 2011-08-25 Nishant Babanrao Naware Stable dosage forms of antihypertensive agents
BRPI0924136B8 (pt) 2009-01-23 2021-05-25 Hanmi Holdings Co Ltd composição farmacêutica sólida compreendendo amlodipina e losartan e método para a preparação da mesma
KR101888692B1 (ko) * 2011-03-25 2018-09-20 한미사이언스 주식회사 로자탄, 암로디핀 및 히드로클로로티아지드를 함유하는 고정 조합 투여 제형 조성물
KR101861307B1 (ko) * 2011-10-13 2018-07-06 한미약품 주식회사 정제를 포함하는 경질 캡슐 복합 제형
KR101907881B1 (ko) 2011-12-30 2018-12-11 한미약품 주식회사 로자탄, 암로디핀 및 히드로클로로티아자이드를 포함하는 고정 용량 조합 제형
KR101392364B1 (ko) * 2012-04-17 2014-05-07 한국유나이티드제약 주식회사 안정성이 향상된 암로디핀 및 로잘탄을 함유하는 복합제 조성물

Also Published As

Publication number Publication date
KR102369607B1 (ko) 2022-03-03
CN107018650B (zh) 2021-02-02
WO2016052866A1 (en) 2016-04-07
PH12017500536A1 (en) 2017-08-07
RU2017114993A (ru) 2018-11-05
ZA201703015B (en) 2019-07-31
DOP2017000084A (es) 2017-07-31
CN107018650A (zh) 2017-08-04
SV2017005417A (es) 2017-10-13
SG11201702364VA (en) 2017-05-30
MX2017004032A (es) 2017-07-07
UY36331A (es) 2016-04-29
MX377103B (es) 2025-03-07
ECSP17022124A (es) 2018-05-31
CN112716951A (zh) 2021-04-30
AR101860A1 (es) 2017-01-18
JP2017530137A (ja) 2017-10-12
US20170326110A1 (en) 2017-11-16
RU2017114993A3 (ar) 2019-04-05
CO2017003913A2 (es) 2017-04-28
US10034862B2 (en) 2018-07-31
RU2698703C2 (ru) 2019-08-29
TW201617075A (zh) 2016-05-16
MY188302A (en) 2021-11-26
TWI681773B (zh) 2020-01-11
CR20170125A (es) 2017-07-06
KR20160038734A (ko) 2016-04-07

Similar Documents

Publication Publication Date Title
WO2015120110A3 (en) Novel pharmaceutical formulations
MD4800B1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
MX2020002271A (es) Composiciones farmaceuticas que comprenden sepiapterina y sus usos de las mismas.
PH12017502376B1 (en) Oral solid formulation containing irinotecan and method of preparing the same
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
WO2014016754A3 (en) Pharmaceutical compositions of proton pump inhibitor
PH12016502246B1 (en) Carboxamide derivatives
WO2014033526A9 (en) Pharmaceutical compositions of etoricoxib
WO2015125152A3 (en) Pharmaceutical compositions of asenapine
MX365216B (es) Forma de dosificacion por via oral de difenhidramina de disolucion rapida.
MX2016001422A (es) Composicion farmaceutica de fingolimod.
WO2015001541A3 (en) Pharmaceutical film composition
PH12017500536A1 (en) Solid pharmaceutical composition comprising amlodipine and losartan
WO2016197042A8 (en) Modified or targeted release formulations of linaclotide
MX340846B (es) Composición de nitazoxanida mejorada y proceso para prepararla.
PH12016502527A1 (en) Stabilized desmopressin
PH12019500779A1 (en) Pharmaceutical complex preparation comprising amlodipine, losartan and rosuvastatin
PH12020550597A1 (en) Formulation having improved hygroscopic property and dissolution rate comprising telmisartan or its pharmaceutically acceptable salt
PH12018502490A1 (en) Oral tipepidine preparation
HK1233927A1 (en) Pharmaceutical formulations of a pan-raf kinase inhibitor, processes for their preparation, and methods of use
GB2541348A (en) Clopidogrel for use in the treatment of benign prostatic hyperplasia
GR1008804B (el) Συνθεσεις για ιατρικη χρηση οι οποιες περιλαμβανουν υαλουρονικο οξυ ή αλατα αυτου, αμινοξεα, βιταμινες, ανοργανα αλατα και αλλα συστατικα
IN2014MU01179A (ar)